{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:15:29Z","timestamp":1761894929432,"version":"3.37.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1097\/wnf.0b013e318197a2f2","type":"journal-article","created":{"date-parts":[[2009,7,28]],"date-time":"2009-07-28T07:54:11Z","timestamp":1248767651000},"page":"219-223","source":"Crossref","is-referenced-by-count":25,"title":["Clozapine-Induced Serositis"],"prefix":"10.1097","volume":"32","author":[{"given":"Fay\u00e7al","family":"Mouaffak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanane","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Pierre","family":"Oli\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Odile","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"9","key":"R1-8-20210203","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1176\/appi.ajp.161.9.1620","article-title":"Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.","volume":"161","author":"Tauscher","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"1","key":"R2-8-20210203","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.yic.0000182114.65134.81","article-title":"Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia.","volume":"21","author":"Kane","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"9","key":"R3-8-20210203","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"issue":"1-2","key":"R4-8-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(01)00212-2","article-title":"Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials.","volume":"56","author":"Tuunainen","year":"2002","journal-title":"Schizophr Res"},{"issue":"2","key":"R5-8-20210203","first-page":"CD000966","article-title":"Newer atypical antipsychotic medication versus clozapine for schizophrenia.","author":"Tuunainen","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"R6-8-20210203","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/oxfordjournals.schbul.a033333","article-title":"Management of the adverse effects of clozapine.","volume":"24","author":"Young","year":"1998","journal-title":"Schizophr Bull"},{"issue":"Suppl 99","key":"R7-8-20210203","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1007\/BF00442571","article-title":"Adverse effects of clozapine.","author":"Grohmann","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"R9-8-20210203","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/01.jcp.0000117430.83724.f9","article-title":"Clozapine-induced lupus erythematosus.","volume":"24","author":"Wolf","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"R10-8-20210203","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1176\/appi.psy.43.5.418","article-title":"Polyserositis, acute withdrawal, and relapse after abrupt clozapine discontinuation.","volume":"43","author":"Malhotra","year":"2002","journal-title":"Psychosomatics"},{"issue":"3","key":"R11-8-20210203","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1176\/appi.ajp.159.3.494","article-title":"Clozapine and pericarditis with pericardial effusion.","volume":"159","author":"Murko","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"1","key":"R12-8-20210203","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1017\/S1461145706006961","article-title":"Late occurrence of clozapine-associated polyserositis.","volume":"10","author":"Waller","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"R13-8-20210203","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1445-5994.2006.01300.x","article-title":"Acute onset of ascites with clozapine-induced hepatitis.","volume":"37","author":"Luo","year":"2007","journal-title":"Intern Med J"},{"issue":"11","key":"R14-8-20210203","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.4088\/JCP.v66n1121a","article-title":"Clozapine-induced pericarditis, pericardial tamponade, polyserositis, and rash.","volume":"66","author":"Bhatti","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"R15-8-20210203","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1176\/ajp.149.9.1274b","article-title":"Polyserositis associated with clozapine treatment.","volume":"149","author":"Daly","year":"1992","journal-title":"Am J Psychiatry"},{"issue":"10","key":"R16-8-20210203","first-page":"1225","article-title":"Malignant neuroleptic syndrome and polyserositis associated to clozapine use: report of one case.","volume":"133","author":"Eymin","year":"2005","journal-title":"Rev Med Chil"},{"issue":"2","key":"R17-8-20210203","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/1044546041649039","article-title":"Pericarditis and polyserositis as a side effect of clozapine in an adolescent girl.","volume":"14","author":"Branik","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"R18-8-20210203","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000096666","article-title":"Clozapine-induced effuso-constrictive pericarditis. Case report and review of the literature.","volume":"108","author":"Rathore","year":"2007","journal-title":"Cardiology"},{"issue":"4","key":"R19-8-20210203","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00002826-199708000-00007","article-title":"Clozapine induced polyserositis.","volume":"20","author":"Catalano","year":"1997","journal-title":"Clin Neuropharmacol"},{"issue":"20","key":"R20-8-20210203","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00004850-199803000-00007","article-title":"Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment.","volume":"13","author":"Thompson","year":"1998","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"R21-8-20210203","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eurpsy.2003.10.003","article-title":"Pericardial and bilateral pleural effusion associated with clozapine treatment.","volume":"19","author":"Boot","year":"2004","journal-title":"Eur Psychiatry"},{"issue":"11","key":"R22-8-20210203","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1176\/appi.ajp.159.11.1947","article-title":"Sweet's syndrome and polyserositis with clozapine.","volume":"159","author":"Schonfeldt-Lecuona","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"1","key":"R23-8-20210203","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2710.2004.00616_1.x","article-title":"Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine.","volume":"30","author":"Wehmeier","year":"2005","journal-title":"J Clin Pharm Ther"},{"issue":"9","key":"R24-8-20210203","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1345\/aph.19038","article-title":"Papular rash and bilateral pleural effusion associated with clozapine.","volume":"33","author":"Stanislav","year":"1999","journal-title":"Ann Pharmacother"},{"issue":"3","key":"R25-8-20210203","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00004714-199706000-00022","article-title":"Cellulitis, eosinophilia, and unilateral pleural effusion associated with clozapine treatment.","volume":"17","author":"Chatterjee","year":"1997","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"R26-8-20210203","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1440-1614.2002.0988f.x","article-title":"Clozapine associated pericarditis and elevated troponin I.","volume":"36","author":"Kay","year":"2002","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"R27-8-20210203","first-page":"46","article-title":"Peri-\/myocarditis with clozapine (Leponex).","volume":"24","author":"Khalil","year":"1997","journal-title":"Psychiatr Prax"},{"issue":"7","key":"R28-8-20210203","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4088\/JCP.v68n0726d","article-title":"Eosinophilia indicating subclinical clozapine-induced pericarditis.","volume":"68","author":"Kortner","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"1184","key":"R29-8-20210203","first-page":"U651","article-title":"Clozapine-associated polyserositis.","volume":"116","author":"Lim","year":"2003","journal-title":"N Z Med J"},{"issue":"6","key":"R30-8-20210203","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/emj.2007.056879","article-title":"Pericardial effusion in patients with schizophrenia: are they on clozapine?","volume":"25","author":"Raju","year":"2008","journal-title":"Emerg Med J"},{"issue":"4-6","key":"R31-8-20210203","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0278-5846(82)80162-0","article-title":"Difficulties in assessing adverse drug reactions in clinical trials.","volume":"6","author":"Naranjo","year":"1982","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"R32-8-20210203","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/00007611-199508000-00023","article-title":"Eosinophilic pleural effusion associated with valproic acid administration.","volume":"88","author":"Kaufman","year":"1995","journal-title":"South Med J"},{"issue":"1","key":"R33-8-20210203","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/tx700186p","article-title":"Idiosyncratic drug reactions: past, present, and future.","volume":"21","author":"Uetrecht","year":"2008","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"R34-8-20210203","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1378\/chest.116.1.212","article-title":"Drugs and the pleura.","volume":"116","author":"Morelock","year":"1999","journal-title":"Chest"},{"issue":"10","key":"R35-8-20210203","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1345\/aph.1K126","article-title":"Characterization and clinical management of clozapine-induced fever.","volume":"41","author":"Lowe","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"9","key":"R36-8-20210203","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00228-002-0523-9","article-title":"Therapeutic drug monitoring data: risperidone does not increase serum clozapine concentration.","volume":"58","author":"Raaska","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"R37-8-20210203","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0920-9964(00)00094-3","article-title":"Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor.","volume":"54","author":"Maes","year":"2002","journal-title":"Schizophr Res"},{"issue":"2-3","key":"R38-8-20210203","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0920-9964(97)00057-1","article-title":"In vivo immunomodulatory effects of clozapine in schizophrenia.","volume":"26","author":"Maes","year":"1997","journal-title":"Schizophr Res"},{"issue":"5","key":"R39-8-20210203","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0022-3956(99)00021-7","article-title":"Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis.","volume":"33","author":"Haack","year":"1999","journal-title":"J Psychiatr Res"},{"issue":"6","key":"R40-8-20210203","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0022-3956(00)00032-7","article-title":"Effects of antipsychotic drugs on cytokine networks.","volume":"34","author":"Pollmacher","year":"2000","journal-title":"J Psychiatr Res"},{"issue":"4","key":"R41-8-20210203","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/sj.tpj.6500179","article-title":"Potential clozapine target sites on peripheral hematopoietic cells and stromal cells of the bone marrow.","volume":"3","author":"Pereira","year":"2003","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"R42-8-20210203","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/01.jcp.0000144891.52858.a6","article-title":"Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis.","volume":"24","author":"Mosyagin","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"R43-8-20210203","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/S0022-3565(25)12207-6","article-title":"Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells.","volume":"275","author":"Liu","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"R44-8-20210203","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0022-3565(24)37177-0","article-title":"Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis.","volume":"283","author":"Williams","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"R45-8-20210203","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0022-3565(25)24566-9","article-title":"Metabolism and bioactivation of clozapine by human liver in vitro.","volume":"272","author":"Pirmohamed","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"R46-8-20210203","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2217\/14622416.9.8.1101","article-title":"Clozapine-induced agranulocytosis and its genetic determinants.","volume":"9","author":"Opgen-Rhein","year":"2008","journal-title":"Pharmacogenomics"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0b013e318197a2f2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T13:36:11Z","timestamp":1739280971000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200907000-00008"}},"subtitle":["Review of Its Clinical Features, Pathophysiology and Management Strategies"],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e318197a2f2","relation":{},"ISSN":["0362-5664"],"issn-type":[{"type":"print","value":"0362-5664"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}